Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?

doi:10.3748/wjg.v18.i35.4944

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 35

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6102)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-10) series, Tables (1-2) series.

Item

Count

PDF

474

HTML

5148

Figures (1-10)

224

Tables (1-2)

256

Sum=6102

Sep 21, 2012 (publication date) through Dec 1, 2024

Times Cited of This Article

Times Cited (60)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Sep 21, 2012; 18(35): 4944-4958
Published online Sep 21, 2012. doi: 10.3748/wjg.v18.i35.4944

Table 1 Characteristics of selected trials

Ref.	Intervention	n	Male (%)	Age (range)	Metastatic (%)	Response rate (%)	Median PFS (mo)	1-yr OS	Median OS (mo)	Quality
Louvet et al[15]	Gem	163	53	60.1 (22-75)	70	17.3	3.7	27.8	7.1	4
Louvet et al[15]	Gem + Oxaliplatin	163	60	61.3 (35-77)	68	26.8	5.8	34.7	9.0	4
Poplin et al[16]	Gem	275	56.4	64 (31-88)	90.2	6	2.6	16	4.9	4
Poplin et al[16]	Gem + Oxaliplatin	272	45.6	63 (29-96)	89.3	9	2.7	21	5.7	4
Heinemann et al[17]	Gem	95	61.9	66 (43-85)	78.9	9.0	3.1	24.7	6.0	4
Heinemann et al[17]	Gem + Cisplatin	95	65.3	64 (37-82)	80	11.5	5.3	25.3	7.5	4
Colucci et al[18]	Gem	54	50	63 (43-75)	65	9.2	2	11	5	4
Colucci et al[18]	Gem + Cisplatin	53	35	60 (33-71)	68	26.4	5	11.3	7.5	4
Colucci et al[19]	Gem	199	56.8	63 (37-75)	82.9	10.1	3.9	34.0	8.3	4
Colucci et al[19]	Gem + Cisplatin	201	62.2	63 (35-75)	84.6	11.4	3.8	30.7	7.2	4
Kulke et al[20]	Gem	64	66	58.9 (31-81)		14	3.3	NR	6.4	4
	Gem + Cisplatin	66	56	58.9 (36-84)	100	13	4.5	NR	6.7
	Gem + Irinotecan	64	68	60.8 (32-77)		14	4.0	NR	7.1
Berlin et al[21]	Gem	162	53.7	64.3 (33-85)	90.1	5.6	2.2	NR	5.4	4
Berlin et al[21]	Gem + 5-fluorouracil	160	51.8	65.8 (28-84)	89.4	6.9	3.4	NR	6.7	4
Herrmann et al[22,24]	Gem	159	53	62 (36-84)	79	8	3.9	30	7.2	4
Herrmann et al[22,24]	Gem + Capecitabine	160	54	62 (27-83)	80	10	4.3	32	8.4	4
Cunningham et al[23]	Gem	266	58	62 (26-83)	71	12.4	3.8	22.0	6.2	4
Cunningham et al[23]	Gem + Capeitabine	267	60	62 (37-82)	70	19.1	5.3	24.3	7.1	4
Scheithauer et al[25]	Gem	42	55	66 (39-75)	100	14	4.0	37.2	8.2	4
Scheithauer et al[25]	Gem + Capeitabine	41	66	64 (40-75)	100	17	5.1	31.8	9.5	4
Costanzo et al[26]	Gem	49	48	64 (34-75)	73	8	3.5	18	7.75	4
Costanzo et al[26]	Gem + 5-fluorouracil	45	63	62 (44-75)	67	11	4.5	20	7.5	4
Abou-Alfa et al[27]	Gem	174	57	62.3 (30-84)	78	5.7	3.8	21	6.2	4
Abou-Alfa et al[27]	Gem + Exatecan	175	53	63.0 (36-85)	79	7.1	3.7	23	6.7	4
Stathopoulos et al[28]	Gem	74	42	64 (44-83)	66	10	2.9	21.8	6.5	4
Stathopoulos et al[28]	Gem + Irinotecan	71	39	64 (31-84)	60	15	2.8	24.3	6.4	4
Lima et al[29]	Gem	180	53.3	60.2 (32-82)	80.6	4.4	3.0	22	6.6	4
Lima et al[29]	Gem + Irinotecan	180	57.2	63.2 (38-81)	82.2	16.1	3.5	21	6.3	4
Moore et al[38]	Gem	284	57	64 (36.1-92)	75.0	8.0	3.55	17	5.91	4
Moore et al[38]	Gem + Erlotinib	285	47.7	63.7 (37-84)	76.5	8.6	3.75	23	6.24	4
Cutsem et al[39]	Gem	347	58	62 (30-88)	77	8	3.6	24	6.06	4
Cutsem et al[39]	Gem + Tipifarnib	341	57	61 (29-89)	76	6	3.7	27	6.43	4
Eckhardt et al[40]	Gem	120	59	60 (35-86)	73	NR	3.03	NR	7.36	5
Eckhardt et al[40]	Gem + Tipifarnib	124	64	63 (35-81)	71	NR	2.3	NR	6.73	5
Philip et al[37]	Gem	371	54	64.3	78	7	3.0	NR	5.9	4
Philip et al[37]	Gem + cetuximab	372	51	63.7	79	8	3.4	NR	6.3	4
Kindler et al[36]	Gem	300	51	65.0 (35-86)	85	10	2.9	NR	5.9	4
Kindler et al[36]	Gem + Bevacizumab	302	58	63.7 (26-88)	84	13	3.8	NR	5.8	4
Kindler et al[35]	Gem	316	59	62 (35-89)	72	1.6	4.4	NR	8.3	5
Kindler et al[35]	Gem + Axitinib	316	61	61 (34-84)	72	4.9	4.4	NR	8.5	5
Spano et al[41]	Gem	34	47	61.0 (36-78)	19	3	3.7	23.5	5.6	4
Spano et al[41]	Gem + Axitinib	69	51	65.0 (44-81)	40	7	4.2	36.8	6.9	4
Friess et al[34]	Gem	43	42	66 (56-80)	91	14	3.83	0.24	7.7	4
Friess et al[34]	Gem + Cilengitide	46	57	68 (40-80)	94	17	3.66	0.15	6.7	4
Richards et al[33]	Gem	44	72.7	64.1 (41-83)	86.4	5.3	3.0	17	5.1	4
Richards et al[33]	Gem + Enzastarin	86	53.5	68.3 (39-86)	90.7	8.6	3.4	19	5.6	4
Bramhall et al[31]	Gem	119	71	62 (37-85)	62	16	3.2	17	5.46	5
Bramhall et al[31]	Gem + Marimastat	120	69	62 (32-83)	59	11	3.08	18	5.51	5
Richards et al[32]	Gem	85	60.2	65 (36-83)	83.0	13.9	3.43	NR	7.13	5
Richards et al[32]	Gem + CA-994	85	59.3	62 (32-82)	82.6	11.8	3.06	NR	6.47	5
Oettle et al[30]	Gem	282	53.5	63 (28-82)	91.1	7.1	3.3	20.1	6.3	4
Oettle et al[30]	Gem + PPemetrexed	283	60.4	63 (27-82)	90.1	14.8	3.9	21.4	6.2	4

NR: No record; PFS: Progression-free survival; OS: Overall survival.

Table 2 Grade 3 or 4 toxicity of selected clinical trials

Ref.	Intervention	Vomiting	Diarrhea	Neutropenia	Anemia	Thrombocytopenia
Louvet et al[15]	Gem	3.2	1.3	27.6	10.3	3.2
Louvet et al[15]	Gem + Oxaliplatin	8.9	5.7	20.4	6.4	14.0
Poplin et al[16]	Gem	7	4	33	10	13
Poplin et al[16]	Gem + Oxaliplatin	16	6	22	6	11
Heinemann et al[17]	Gem	5.9	4.7	NR	10.6	10.6
Heinemann et al[17]	Gem + Cisplatin	22.2	3.3	NR	13.3	4.4
Colucci et al[18]	Gem	2	0	9	4	2
Colucci et al[18]	Gem + Cisplatin	2	4	18	6	2
Colucci et al[19]	Gem	< 1	1.5	13.7	1	18.9
Colucci et al[19]	Gem + Cisplatin	2.6	< 1	24.7	4.8	15.3
Kulke et al[20]	Gem	24.1	NR	82.8	20	43.1
	Gem + Cisplatin	29	NR	74.2	25.8	79
	Gem + Irinotecan	16.7	NR	41.7	8.3	23.3
Berlin et al[21]	Gem	8	NR	5	10	11
Berlin et al[21]	Gem + 5-fluorouracil	7	NR	7	10	19
Herrmann et al[22,24]	Gem	4	2	19	6	8
Herrmann et al[22,24]	Gem + Capeitabine	4	5	23	8	4
Cunningham et al[23]	Gem	6	4	22	6	6
Cunningham et al[23]	Gem + Capeitabine	6	5	35	4	11
Scheithauer et al[25]	Gem	0	0	7.6	0	2.5
Scheithauer et al[25]	Gem + Capeitabine	0	5	10	5	0
Costanzo et al[26]	Gem	0	0	2	6	0
Costanzo et al[26]	Gem + 5-fluorouracil	2	0	2	7	2
Abou-Alfa et al[27]	Gem	3.1	< 1	14.6	7.6	4.4
Abou-Alfa et al[27]	Gem + Exatecan	5.3	1.1	30.3	5.9	15.4
Stathopoulos et al[28]	Gem	1.4	2.8	15.7	4.2	0
Stathopoulos et al[28]	Gem + Irinotecan	1.6	3.2	26.6	5	5
Lima et al[29]	Gem	8.2	1.8	31.9	13	14.2
Lima et al[29]	Gem + Irinotecan	13.9	18.5	37.6	16.2	19.6
Moore et al[38]	Gem	NR	< 1	27%	NR	11%
Moore et al[38]	Gem + Erlotinib	NR	2	24%	NR	10%
Cutsem et al[39]	Gem	9	3	30	16	12
Cutsem et al[39]	Gem + Tipifarnib	7	4	40	20	15
Eckhardt et al[40]	Gem	9.3	0	33.9	11	15.3
Eckhardt et al[40]	Gem + Tipifarnib	4	0	35.5	12.1	16.1
Philip et al[37]	Gem	2.2	2.5	23.9	6.2	8.5
Philip et al[37]	Gem + cetuximab	6.6	2.8	23.3	9.7	6.6
Kindler et al[36]	Gem	NR	NR	29	8	12
Kindler et al[36]	Gem + Bevacizumab	NR	NR	33	5	12
Kindler et al[35]	Gem	3.2	1.6	< 1	< 1	< 1
Kindler et al[35]	Gem + Axitinib	3.9	1.3	0	0	0
Spano et al[41]	Gem	10	0	33	17	13
Spano et al[41]	Gem + Axitinib	6	6	28	8	20
Richards et al[33]	Gem	0	2.6	28.2	5.1	25.6
Richards et al[33]	Gem + Enzastarin	2.4	3.7	18.3	3.7	14.6
Bramhall et al[31]	Gem	14%	NR	NR	7%	NR
Bramhall et al[31]	Gem + Marimastat	6%	NR	NR	3%	NR
Richards et al[32]	Gem	9	3	NR	5	11
Richards et al[32]	Gem + CA-994	9	5	NR	13	2
Oettle et al[30]	Gem	3.7	0.7	12.8	2.9	6.2
Oettle et al[30]	Gem + Pemetrexed	3.3	2.9	45.1	13.9	17.9

NR: No record.

Citation: Sun C, Ansari D, Andersson R, Wu DQ. Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer? World J Gastroenterol 2012; 18(35): 4944-4958
URL: https://www.wjgnet.com/1007-9327/full/v18/i35/4944.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i35.4944